Search Result

Isoforms Recommended:	PKD1

Results for "

PKD1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) PDK-1 (1) Pim (3) PKC (1) PKD (14) Small Interfering RNA (siRNA) (6)
By Research Areas:	Cancer (10) Cardiovascular Disease (2) Inflammation/Immunology (3) Metabolic Disease (2)
Oligonucleotides:	Pre-designed siRNA Sets (6) siRNAs (6)

Inhibitors & Agonists

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-118052

BPKDi	PKD	Cardiovascular Disease
BPKDi is a potent bipyridyl *PKD* inhibitor with IC₅₀s of 1 nM, 9 nM and 1 nM for PKD1, PKD2 and PKD3, respectively. BPKDi blocks signal-dependent phosphorylation and nuclear export of class IIa HDACs in cardiomyocytes ^[1].

HY-12239

CID755673 Maximum Cited Publications 7 Publications Verification	PKD	Cancer
CID755673 is a potent *PKD* inhibitor with IC₅₀s of 182 nM, 280 nM and 227 nM for *PKD1, PKD2* and *PKD3*, respectively.

HY-131962A

PKD-IN-1 dihydrochloride	PDK-1	Metabolic Disease Cancer
PKD-IN-1 dihydrochloride (compound 32), an aminoethylamino-aryl (AEAA) compound, acts as *PKD-1* inhibitor. PKD-IN-1 can be used for protein kinase D (PKD)-mediated diseases research ^[1].

HY-RS00002

Pkd1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) PKD	Others
Pkd1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pkd1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pkd1 Mouse Pre-designed siRNA Set A Pkd1 Mouse Pre-designed siRNA Set A

HY-RS00003

PKD1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) PKD	Others
PKD1 Human Pre-designed siRNA Set A contains three designed siRNAs for PKD1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PKD1 Human Pre-designed siRNA Set A PKD1 Human Pre-designed siRNA Set A

HY-RS00004

Pkd1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) PKD	Others
Pkd1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Pkd1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pkd1 Rat Pre-designed siRNA Set A Pkd1 Rat Pre-designed siRNA Set A

HY-RS00005

PKD1L1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PKD1L1 Human Pre-designed siRNA Set A contains three designed siRNAs for PKD1L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PKD1L1 Human Pre-designed siRNA Set A PKD1L1 Human Pre-designed siRNA Set A

HY-RS00006

PKD1L2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PKD1L2 Human Pre-designed siRNA Set A contains three designed siRNAs for PKD1L2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PKD1L2 Human Pre-designed siRNA Set A PKD1L2 Human Pre-designed siRNA Set A

HY-RS00007

PKD1L3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PKD1L3 Human Pre-designed siRNA Set A contains three designed siRNAs for PKD1L3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PKD1L3 Human Pre-designed siRNA Set A PKD1L3 Human Pre-designed siRNA Set A

HY-131962

PKD-IN-1	PKD	Metabolic Disease Cancer
PKD-IN-1 (compound 32), an aminoethylamino-aryl (AEAA) compound, acts as *PKD-1* inhibitor. PKD-IN-1 can be used for protein kinase D (PKD)-mediated diseases research ^[1].

HY-15698A

CRT0066101 dihydrochloride 2 Publications Verification	PKD Pim Apoptosis	Inflammation/Immunology Cancer
CRT0066101 dihydrochloride is a potent and orally active *PKD* inhibitor with IC₅₀ values of 1 nM, 2.5 nM and 2 nM for *PKD1, PKD2, and PKD3, respectively ^[1]. CRT0066101 dihydrochloride is also a potent PIM2* inhibitor with an IC₅₀ of ~135.7 nM. CRT0066101 dihydrochloride exhibits anti-inflammatory activity in mice LPS (HY-D1056)-induced lung injury models, and has anticancer effects ^[1] .

HY-15698

CRT0066101 2 Publications Verification	PKD Pim Apoptosis	Inflammation/Immunology Cancer
CRT0066101 is a potent and orally active *PKD* inhibitor with IC₅₀ values of 1 nM, 2.5 nM and 2 nM for *PKD1, PKD2, and PKD3, respectively ^[1]. CRT0066101 is also a potent PIM2* inhibitor with an IC₅₀ of ~135.7 nM. CRT0066101 exhibits anti-inflammatory activity in mice LPS (HY-D1056)-induced lung injury models, and has anticancer effects ^[1] .

HY-15698B

CRT0066101 trihydrochloride	PKD Pim Apoptosis	Inflammation/Immunology Cancer
CRT0066101 trihydrochloride is the trihydrochloride salt form of CRT0066101 (HY-15698). CRT0066101 trihydrochloride is an orally active *PKD* inhibitor with IC₅₀ values of 1 nM, 2.5 nM and 2 nM for *PKD1, PKD2, and PKD3, respectively. CRT0066101 trihydrochloride is also an inhibitor for PIM2* with an IC₅₀ of ~135.7 nM. CRT0066101 trihydrochloride exhibits anti-inflammatory activity in mice LPS (HY-D1056)-induced lung injury models, and has anticancer effects ^[1] .

HY-151374

3-IN-PP1	PKD	Cancer
3-IN-PP1 is a protein kinase D (PKD) inhibitor. 3-IN-PP1 has potent pan-PKD inhibitory activity for PKD1, PKD2 and PKD3 with IC₅₀ values of 108, 94 and 108 nM, respectively. 3-IN-PP1 also is a broad spectrum anticancer agent and has inhibition of several tumor cells growth. 3-IN-PP1 can be used for the research of cancer ^[1].

HY-15528

kb NB 142-70	PKD	Cancer
kb NB 142-70 is a potent *PKD* inhibitor, with IC₅₀s of 28.3, 58.7 and 53.2 nM for PKD1, PKD2, and PKD3, respectively. kb NB 142-70 also has antitumor activity.

HY-112547

CRT5 CRT0066051	PKD	Others
CRT5, a pyrazine benzamide, is a potent and selective inhibitor for all three isoforms of *PKD* in endothelial cells treated with VEGF (IC₅₀s = 1, 2, and 1.5 nM for PKD1, PKD2, and PKD3, respectively). CRT5 decreases VEGF-induced endothelial migration, proliferation and tubulogenesis ^[1].

HY-128142

*PKC/PKD-IN-1*	PKD PKC	Cardiovascular Disease
PKC/PKD-IN-1 (Compound 13C) is an orally active dual protein kinase C/D (PKC/PKD) inhibitor with an IC₅₀ value of 0.6 nM for *PKD1. PKC/PKD*-IN-1 can attenuate high-salt diet-induced cardiac hypertrophy and can be used in the study of heart failure ^[1].

HY-13454

CID 2011756	PKD	Cancer
CID 2011756 is an ATP competitive *PKD* inhibitor, with an IC₅₀ of 3.2 μM for PKD1 in cell free assay, and also shows cellular pan-PKD inhibitory activity against PKD2 and PKD3 (IC₅₀, 0.6 and 0.7 μM, respectively). CID 2011756 also has antitumor activity.

HY-117051

STA-2842	Others	Cancer
STA-2842 is a small molecule agent that inhibits heat shock protein 90 (HSP90) to treat autosomal dominant polycystic kidney disease (ADPKD). The disease is caused by inherited mutations in the PKD1 or PKD2 genes that aberrantly activate multiple signaling proteins and pathways that regulate cell proliferation. Through network construction, we found that many HSP90 client proteins associated with ADPKD are regulated by HSP90. STA-2842 induced degradation of these clients in Pkd1?/? primary kidney cells and in vivo. In experiments using conditional Cre-mediated in vivo knockout of Pkd1 in mice, we found that weekly administration of STA-2842 for 10 weeks significantly reduced initial renal cyst formation and kidney growth in mice and slowed disease progression in mice with pre-existing cysts. These improved disease phenotypes were accompanied by improvements in renal function markers and reductions in the expression and activity of HSP90 clients and their effectors, with the extent of this inhibition correlating with the extent of cyst expansion in individual animals. Pharmacokinetic analysis showed that HSP90 was overexpressed in cystic kidney tissue and HSP90 inhibitors were selectively retained in cystic tissue, which is similar to the situation in solid tumors. These results provide a preliminary basis for evaluating HSP90 inhibitors as therapeutic agents for ADPKD.

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81914

	PKD1 Antibody (YA1659) PRKD1; PKD; PKD1; PRKCM; Serine/threonine-protein kinase D1; Protein kinase C mu type; Protein kinase D; nPKC-D1; nPKC-mu	WB	Human, Rat
	PKD1 Antibody (YA1659) is a biotin-conjugated non-conjugated IgG antibody, targeting PKD1, with a predicted molecular weight of 102 kDa (observed band size: 102 kDa). PKD1 Antibody (YA1659) can be used for WB experiment in human, rat background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Pkd1 Mouse Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
Pkd1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pkd1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

PKD1 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PKD1 Human Pre-designed siRNA Set A contains three designed siRNAs for PKD1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pkd1 Rat Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
Pkd1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Pkd1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

PKD1L1 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PKD1L1 Human Pre-designed siRNA Set A contains three designed siRNAs for PKD1L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PKD1L2 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PKD1L2 Human Pre-designed siRNA Set A contains three designed siRNAs for PKD1L2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PKD1L3 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PKD1L3 Human Pre-designed siRNA Set A contains three designed siRNAs for PKD1L3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.